Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.
about
Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations.Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence.An LC-MS/MS method for rapid and sensitive high-throughput simultaneous determination of various protein kinase inhibitors in human plasma.Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer.Prospective Analysis in GIST Patients on the Role of Alpha-1 Acid Glycoprotein in Imatinib ExposurePersonalizing chemotherapy dosing using pharmacological methods.Therapeutic drug monitoring of targeted anticancer therapy.Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review.Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure.Harnessing Solute Carrier Transporters for Precision Oncology.Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients.Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours.Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662.Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma.Dried blood spot analysis for therapeutic drug monitoring of pazopanib.Urinary Dopamine as a Potential Index of the Transport Activity of Multidrug and Toxin Extrusion in the Kidney.An Automated Homogeneous Immunoassay for Quantitating Imatinib Concentrations in Plasma.Therapeutic drug monitoring and tyrosine kinase inhibitors.Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization.Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib.Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour Patients.Development and validation of a liquid chromatography-tandem mass spectrometry analytical method for the therapeutic drug monitoring of eight novel anticancer drugs.How 'Optimal' are Optimal Sampling Times for Tyrosine Kinase Inhibitors in Cancer? Practical Considerations.What do we need to make genetic biomarker-guided treatment for renal cell carcinoma a reality?A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma.Patient-reported outcome measures in a pharmacokinetic study with sunitinib, a prospective cohort study.BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen.Levofloxacin effect on erlotinib absorption. Evaluation of the interaction in undernutrition situations through population pharmacokinetic analysis in rats.The Use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients.Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients.Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib.A high throughput immunoassay for the therapeutic drug monitoring of tegafur
P2860
Q33418378-3F647E46-AC12-4224-A026-BD2FA5CE8E6DQ35023711-44091507-B67E-4BE2-B634-FD9274447345Q35884179-B159633D-7EB2-4EB2-851B-83E5D43A34CCQ36083906-5B5AA0B6-B95D-4026-81F2-B1015E9EDC10Q37038195-EB35D21A-CA70-40F3-BFD6-A3005FE63D13Q37650706-D1527818-9D62-4250-A978-AE908DA211FFQ38571728-7B96165E-F894-4ECB-848F-61B5A9F80985Q38579278-5D024AE4-6214-450F-A4D9-6D735A7EFCB1Q38836158-2E41179E-21D6-4A72-B086-A759DD2FF130Q38937228-5498912C-3672-4B3E-B56A-A24D1AF2D520Q39204754-EAD74871-0B0E-4CED-8156-89DCFB7815E6Q39429946-C45CC2D2-4111-40E1-AFEB-B8AEF30955BDQ39480956-921B6594-106D-47BF-8F40-EEEE79F3CF03Q39688034-9D9DD57C-E1D1-44EA-A9CC-662A0E032B56Q40126912-93FCB682-E779-42E9-9E79-0EE2F1C4CC96Q40698804-ECC51985-2495-49DE-9E0E-A53548A1C5A7Q40881271-DDAE7CEC-CAFF-4C8D-8E9C-729249168E5CQ40952339-6714F565-797C-42DD-9BE7-6317E3E68323Q41568738-E9C183A0-DEAE-4D0E-A76B-3E31EEF6FCF1Q41846251-BEAA7281-4B39-4CE3-959E-B301824FFA6DQ47131757-9542C0B6-8F52-44E6-9AA1-62BF9F1C6D08Q47847397-A4DABAC2-49BE-4B7C-BA86-7094CA8913CFQ47969048-9B7787D0-007E-498E-8C17-5E493BB68FB9Q48152547-B9E0A055-EB82-4CAA-AE0E-249DDD859C89Q48254413-413F5C9E-C893-4BDC-B606-9D4C64E82DDCQ48826707-608A0923-4712-4BB6-A918-0FCFF6BD549EQ49394586-D476807F-B7BC-47BF-958A-9DAE48C2DE2CQ49473156-94AA4A34-9B6D-42DA-AFB8-86D0E1379D1EQ49722763-C59D9001-1201-49F6-AE79-3E35C3DEB943Q50600192-8F6F63C9-787C-4CE0-8422-F8AAC18E34AFQ50947265-4D03E667-49F8-4C82-8F62-5ED0C719F183Q52883050-877472A3-C352-4AB8-82F7-E105A7BF2936Q53581485-8B5D2CCA-9354-4DFE-AD4F-814B5FE463C1Q53669584-6F2C7AF0-251C-40E4-9AAB-6550B34E6CECQ59260473-B067C63C-D826-4EE8-A7BD-1A92FB2DA14A
P2860
Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Practical guidelines for thera ...... n the pharmacokinetic targets.
@en
type
label
Practical guidelines for thera ...... n the pharmacokinetic targets.
@en
prefLabel
Practical guidelines for thera ...... n the pharmacokinetic targets.
@en
P2093
P2860
P1476
Practical guidelines for thera ...... n the pharmacokinetic targets.
@en
P2093
Alwin D R Huitema
Cynthia M Nijenhuis
Jan H M Schellens
Jos H Beijnen
Neeltje Steeghs
P2860
P2888
P304
P356
10.1007/S40262-014-0137-2
P577
2014-04-01T00:00:00Z
P5875
P6179
1019983223